Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from Silybum marianum

Phytotherapy Research

Volumn 17, Issue 5, 2003, Pages 524-530

  Švagera, Zdeněk ^a   Škottová, Nina ^a   Váňa, Petr ^a   Večeřa, Rostislav ^a   Urbánek, Karel ^a   Belejová, Marie ^a   Kosina, Pavel ^a   Šimánek, Vilím ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Plasma lipoproteins; Silibinin; Silibinin phosphatidylcholine complex; Silybum marianum

Indexed keywords

ALBUMIN; ANTIOXIDANT; CHYLOMICRON; FLAVONOLIGNAN; HIGH DENSITY LIPOPROTEIN; IODINE 125; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLIVE OIL; SILIBININ; SILYBUM MARIANUM EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG LABELING; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG UPTAKE; FRACTIONATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; LIPOPHILICITY; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; NONHUMAN; RADIOACTIVITY; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

SILYBUM MARIANUM;

EID: 0038526393     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1187     Document Type: Article

References (30)

1. Bachner-Jaschke I, Koch H. 1979. Binding of silymarin substances to plasma proteins and synthetic polymers. Arch Pharm 312: 954-958.
2. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. 1990. Pharmacokinetic studies on IdB 1016, a silybin - phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokin 15: 333-338.
3. Carbonneau MA, Leger CL, Monnier L, et al., 1997. Supplementation with wine phenolic compounds increases antioxidant capacity of plasma and vitamin E of low-density lipoprotein without changing the lipoprotein Cu(2+) - oxidizability: possible explanation by phenolic location. Eur J Clin Nutr 51: 682-690.
4. Drevon CA. 1991. Absorption, transport and metabolism of vitamin E. Free Radic Res Commun 14: 229-246.
5. Duthie G, Crozier A. 2000. Plant-derived phenolic antioxidants. Curr Opin Lipidol 11: 43-47.
6. Fleisher S, Kervina M. 1974. Subcellular fractionation of rat liver. In Methods in Enzymology, Fleisher S, Packer L (eds). Academic Press: New York; 6-41.
7. Flora K, Hahn M, Rosen H, Benner K. 1998. Milk thistle (Silybum marianum) for the therapy of liver diseases. Am J Gastroenterol 93: 139-143.
8. Havel RJ, Eder HA, Bragdon JH. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353.
9. Hultin M, Carnheim C, Rosenqist K, Olivecrona T. 1995. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res 36: 2174-2184.
10. Kosina P, Bartek J. 2000. Determination of silybin in blood plasma using high performance liquid chromatography with solid phase extraction. Chem Listy 94: 1115-1117.
11. Krečman V, Škottová N, Walterová D, Ulrichová J, Šimánek V. 1998. Silymarin inhibits the development of diet-induced hypercholesterolemia in rat. Planta Med 64: 138-142.
12. Lairon D, Amiot MJ. 1999. Flavonoids in food and natural antioxidants in wine. Curr Opin Lipidol 10: 23-28.
13. Locher R, Suter PM, Weyhenmeyer R, Vetter W. 1998. Inhibitory action of silibinin on low density lipoprotein oxidation. Arzneim-ittelforsch/Drug Res 48: 236-239.
14. Mao SJT, Yates MT, Rechtin AE, Jackson RL, Van Sickle WA. 1991. Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J Med Chem 34: 298-302.
15. Miyagi Y, Miwa K, Inouc H. 1997. Inhibition of human low-density lipoprotein oxidation by flavonoids in red wine and grape juice. Am J Cardiol 80: 1627-1631.
16. Morazzoni P, Magistretti MJ, Giachetti C, Zanolo G. 1992. Comparative bioavailability of Silipide, a new flavonolignan complex, in rats. Eur J Drug Metab Pharm 17: 39-44.
17. Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. 1993. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharm 18: 289-297.
18. Orlando R, Fragasso A, Lampertico M, Marena C. 1990. Silybin kinetics in patients with liver cirrhosis: a comparative study of a silybin - phosphatidylcholine complex and silymarin. Med Sci Res 18: 861-863.
19. Perugini C, Bagnati M, Cau C, et al., 2000. Distribution of lipid-soluble antioxidants in lipoproteins from healthy subjects. Pharmacol Res 41: 53-63.
20. Škottová N, Krečman V. 1998. Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palacki Olomuc 141: 39-40.
21. Škottová N, Krečman V. Šimánek V. 1999. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res 13: 535-537.
22. Škottová N, Krečman V, Váňa P, Chmela Z, Ulrichová J, Šimánek V. 2000. Effect of silymarin and silibinin-phosphatidylcholine complex on plasma and lipoprotein cholesterol, and oxidation of LDL in rats fed on high cholesterol diet supplemented with currant oil. Acta Univ Palacki Olomuc 144: 55-58.
23. Škottová N, Savonen R, Lookene A, Hultin M, Olivecrona G. 1995. Lipoprotein lipase enhances removal of chylomicrons and chylomicron remnants by the perfused rat liver. J Lipid Res 36: 1334-1344.
24. Škottová N. Švagera Z, Večeřa R, Urbánek K, Jegorov A, Šimánek V. 2001. Pharmacokinetic study of iodine-labeled silibinins in rat. Pharmacol Res 44: 247-253.
25. Valenzuela A, Garrido A. 1994. Biochemical bases of the pharmacological action of the flavonoid silymarin and its structural isomer silibinin. Biol Res 27: 105-112.
26. Van Acker SA, Boven E, Kuiper K, et al. 1997. Monohydroxyethylrutoside, a dose dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Can Res 3: 1747-1754.
27. Wasan KM, Cassidy SM. 1998. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci 87: 411-424.
28. Witztum JL. 1993. The oxidation hypothesis of atherosclerosis. Atherosclerosis 98: 1-9.
29. Yamamoto K, Fukuda N, Shiroi S, et al. 1994. Effects of dietary fat levels on the absorption and tissue accumulation of probucol in the rat. Arzneim-ittelforsch/Drug Res 44: 1059-1062.
30. Zhao J, Agarwall R. 1999. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase 11 enzymes: implications in cancer chemoprevention. Carcinogenesis 20: 2101-2108.